The study has been designed with the help of experts from Germany, UK, Italy, Poland, Moldova, and Indonesia. SMILE study is being conducted in four dental clinics across four different countries (Italy, Poland, Moldova, and Indonesia). Volunteer enrollment was completed in August 2023 and results will be expected to be available in 2025.
On Tuesday, February 20th, the MAGNIFICAT Project, coordinated by CoEHAR, hosted a pivotal workshop in Warsaw, Poland, to bring together all partners involved in in-depth discussions and hands-on exercises focusing…
Data confirms that there is high certainty that nicotine electronic cigarettes increases quit rates compared to nicotine replacement therapy.
The CoEHAR Council (made up of 71 of the 95 members of the Center of Excellence of the University of Catania), meeting in an online session, reconfirmed their trust in…
The COEHAR founder, prof. Riccardo Polosa, in collaboration with experts from US (Floe Foxon, Ray S. Niaura, K. Michael Cummings, Michael Siegel and Neal Benowitz) published a commentary to analyze data and methodologies used to support the paper’s conclusions.
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
In their work “Respiratory health effects of e-cigarette substitution for tobacco cigarettes: a systematic review”, researchers analyzed 16 studies from 20 publications: most of the studies showed no difference in respiratory parameters. This indicates that electronic nicotine delivery systems substitution for smoking likely does not result in additional harm to respiratory health.
Replica researchers performed a standard toxicology battery of three assays used for product assessment and regulatory applications.
According the authors, for every 100 people, 10 to 19 are likely to quit using an e-cigarette; 12 to 16 using varenicline; and 10 to 18 using cytisine. This is compared to the 6 in 100 people likely to quit when using no medicine/e-cigarette or placebo. People using two forms of nicotine replacement therapy at the same time, for example, a combination of nicotine patch and nicotine gum, seemed to have similar rates of quitting to people using e-cigarettes, varenicline and cytisine.
According to prof. Riccardo Polosa, CoEHAR founder: "This small qualitative research simply found what we already knew: that young people are eager to explore new experiences, with vaping potentially being one of them. A critical limitation of this research is the absence of insights into how these participants have been educated about the health implications and addictive nature of nicotine/vaping. To work towards a smoke-free world, it's essential that our messaging on vaping's risk-to-benefit ratio is both accurate and truthful"
We will send you direct emails, without intermediary services, you can withdraw any time.
Copyright 2021 – Center of Excellence for the acceleration of Harm Reduction. All rights reserved.